CSL (ASX:CSL) share price edges lower on annual R&D update

The CSL Limited (ASX:CSL) share price is on the move on Tuesday after the release of its R&D update for 2020…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is on the move this morning following the release of its research and development (R&D) investor briefing.

At the time of writing, the biotherapeutics company's shares are down 0.3% to $303.15.

What was in the update?

This morning CSL released a comprehensive update on all its R&D activities. This includes its work across a number of programs to prevent and treat COVID-19 such as UQ/CSL V451 and AZD1222.

UQ/CSL V451 is a recombinant virus spike protein (molecular clamp technology) formulated with MF59 adjuvant under a partnership with the University of Queensland and the Coalition for Epidemic Preparedness Innovations (CEPI). Phase 1 trials are ongoing, with phase 2 and 3 trials expected in December if everything goes to plan.

AZD1222 is an adenovirus vector designed to express spike protein of COVID-19 virus in situ. It has partnered with AstraZeneca on this one. It is currently undergoing phase 3 trials.

What else did CSL talk about?

CSL revealed that its AEGIS-II Phase 3 study of CSL112 (ApoA-1) for the treatment of acute coronary syndrome has now resumed following a COVID-19 related pause.

More than 10,000 people have been enrolled to date. It is aiming to launch the product in 2023-2025.

Management also spoke about the results of its Phase 2 clinical trials of Garadacimab, a treatment in hereditary angioedema (HAE).

It advised that Garadacimab met its primary end points, with a statistically significant reduction in HAE attacks. It also sees opportunities for the therapy in the treatment of fibrotic disease, cardiovascular disease, and inflammatory disease.

Finally, another topic of interest was the aquisition of Clazakizumab (CSL300) earlier this year. It is an anti-interleukin-6 monoclonal antibody being used in the IMAGINE Phase 3 trial for the treatment of chronic active antibody-mediated rejection. This is the leading cause of long-term rejection in kidney transplant recipients.

In June, Goldman Sachs estimated that Clazakizumab, if successful, could generate peak non-risk adjusted sales of US$5.4 billion by FY 2032 and risk adjusted sales of US$1.3 billion.

Based on trials to date, management appears optimistic that the therapy could improve outcomes for transplant recipients.

Foolish Takeaway.

Overall, based on this pipeline, CSL appears well-placed to both save lives and generate strong returns for investors over the 2020s.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Share Market News

Buy these excellent ASX dividend shares for 5%+ yields

Analysts expect above-average dividend yields from these shares.

Read more »

Two miners examine things they have taken out the ground.
Broker Notes

Up 64% this year! What's Macquarie's price target for Lynas Rare Earths shares?

Clouds on the horizon?

Read more »

Man ponders a receipt as he looks at his laptop.
Opinions

3 reasons why the Xero share price could be a strong buy

This stock has all the hallmarks of a long-term winner.

Read more »

a group of people in business attire gather around a computer in an office environment with expressions of concern as they try to nut out the answer to a challenge they are facing.
Broker Notes

Leading broker just downgraded the Fortescue share price. Is it time to sell?

Downside ahead for the iron ore titan?

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market today.

Read more »

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today
Broker Notes

Broker tips Domino's Pizza share price to rise 54% in FY26

Ord Minnett says the current Domino's Pizza share price offers "very attractive value".

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Market News

Top fund manager backs these 3 ASX 200 shares to shine in FY26

Let’s see who they are.

Read more »

Worker working on a gas pipeline.
Share Market News

Macquarie predicts 26% upside for this ASX utilities stock

Here’s what’s behind the brokers recommendation.

Read more »